Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.75 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL5665165 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4394541 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4664449 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL3049775 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4946381 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL15322750 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL15322747 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| D-Leucine SCHEMBL1537345 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL2154089 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL625031 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHONGQING UPGRA BIOLOGICAL SCI. & TECH., LTD. (CN) | 2020-08-20 | — | — | US | claimed |
| EP-3677284-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chongqing Upgra Biological Sci.&Tech., Ltd. (CN) | 2020-07-08 | — | — | EP | claimed |
| EP-2796544-B1 | Tissue engineering methods and compositions | UNIV DUKE (US) | 2019-04-03 | — | — | EP | claimed |
| US-9649409-B2 | Tissue engineering methods and compositions | CYTEX THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-3074415-A1 | NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES | Agency For Science, Technology And Research (SG) | 2016-10-05 | — | — | EP | claimed |
| WO-2015080670-A1 | NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-04 | — | — | WO | claimed |
| EP-2796544-A1 | Tissue engineering methods and compositions | Duke University (US) | 2014-10-29 | — | — | EP | claimed |
| US-20140227336-A1 | Tissue Engineering Methods and Compositions | CYTEX THERAPEUTICS, INC. (US) | 2014-08-14 | — | — | US | claimed |
| US-20090196901-A1 | Tissue Engineering Methods and Compositions | CYTEX THERAPEUTICS, INC. | 2009-08-06 | — | — | US | claimed |
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1874222-A1 | THREE-DIMENSIONAL FIBER SCAFFOLDS FOR TISSUE ENGINEERING | Duke University (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2007030811-A2 | TISSUE ENGINEERING METHODS AND COMPOSITIONS | DUKE UNIVERSITY (US) | 2007-03-15 | — | — | WO | claimed |
| US-20070041952-A1 | Three-dimensional fiber scaffolds for tissue engineering | DUKE UNIVERSITY (US) | 2007-02-22 | — | — | US | claimed |
| WO-2006113642-A1 | THREE-DIMENSIONAL FIBER SCAFFOLDS FOR TISSUE ENGINEERING | DUKE UNIVERSITY (US) | 2006-10-26 | — | — | WO | claimed |
| WO-2002007961-A1 | THREE-DIMENSIONAL FIBER SCAFFOLDS FOR INJURY REPAIR | 3TEX, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| CN-1300220-A | Peptide compositions and formulations and use of same | MRS LTD (US) | 2001-06-20 | — | — | CN | claimed |
| WO-1996004297-A9 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1996-05-02 | — | — | WO | claimed |
| WO-1994021816-A1 | TEST KITS AND METHODS FOR RAPIDLY TESTING FOR CONTAMINATION BY MICROORGANISMS | ENVIROCON INTERNATIONAL INCORPORATED (US) | 1994-09-29 | — | — | WO | claimed |
| WO-2023166975-A1 | PEPTIDE COMPOUND PRODUCTION METHOD | 国立大学法人徳島大学 | 2023-09-07 | — | — | WO | disclosed |
| US-4382081-A | ANTIARRTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261588-A1 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, SLC11A2 | SLC7A5 322/4885SLC1A3 3109/4885SLC1A2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.